Mode
Text Size
Log in / Sign up
Phase 1 Completed N=30 Randomized Treatment

Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Zolpidem Tartrate Tablets Under Fed Conditions

Healthy
Source: ClinicalTrials.gov NCT00939367 ↗
Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Nov 2013
Primary outcomePrimary: Maximum Plasma Concentration (Cmax) — 130.58; 124.53 ng/mL

Summary

Subjects to compare the single dose bioavailability of Torrent's Zolpidem Tartrate Tablets 10mg and Ambien® Tablets 10 mg of Sanofi-Synthelabo Inc.

Outcome Measures

OutcomeResultp-value
PRIMARY
Maximum Plasma Concentration (Cmax)
130.58; 124.53
PRIMARY
Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]
734.29; 705.45
PRIMARY
The Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity AUC(0-∞)
776.65; 734.01

Eligibility Criteria

Inclusion Criteria

  • The subjects who qualify for the study should meet the following inclusion criteria.
  • Male and female subjects in the range of 18 - 45 years of age.
  • Subjects having Body Mass Index (BMI) in a range of 18.5 to 24.9.
  • Subjects with normal findings as determined by baseline history, physical examination and vital signs (blood pressure, pulse rate, respiration rate and body temperature)
  • Subjects with normal findings as determined by hematological tests, serum chemistry, urine analysis, ECG and X-ray.
  • Willingness to follow the protocol requirement as evidenced by written, informed consent.
  • Agreeing to, not using any medication prescription and over the counter medicines including vitamins and minerals for 14 days prior to study and during the course of the study.
  • No history or presence of significant alcoholism or drug abuse in the past one year.
  • Non-smokers, ex smokers and light smokers will be included. " Light smokers are defined as someone smoking 10 cigarettes or less per day, ex smokers as someone who completely stopped smoking for at least 3 months.

Exclusion Criteria

  • The subjects who qualify for the study should not meet the following exclusion criteria:
  • Requiring medication for any ailment including enzyme-modifying drugs in the previous 28 days, before day1.
  • Any medical or surgical conditions, which might significantly interfere with the functioning of gastrointestinal tract, blood-forming organs etc.
  • History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic diseases.
  • Participation in a clinical drug study or bioequivalence study 90 days prior to present study.
  • History of malignancy or other serious diseases.
  • Refusal to abstain from food for at least ten (10) hours prior to High Fat Breakfast and for additional four (4) hours post dose during each study period.
  • Refusal to abstain from water for at least one (1) hour prior to study drug administration on each study period and for at least two (2) additional hours, post dosing.
  • Any contraindication to blood sampling.
  • Use of xanthine-containing beverages or food and grapefruit juice for 48 hours prior to each drug dose.
  • Blood donation 90 days prior to the commencement of the study.
  • Subjects with positive HIV tests, HbsAg or Hepatitis-C tests.
  • Known history of hypersensitivity to zolpidem Tartrate or to any of the inactive ingredients in the formulation.
  • Refusal to abstain from smoking or consumption of tobacco products 24 hours before dosing until last sample collection of each period.
  • Pregnant and lactating women.
  • Use of prescription medication within 14 days prior to administration of study medication or over the counter products (including natural food supplements,vitamins, garlic as a supplement) within 14 days prior to administration of study medication, except for topical products without systemic absorption.
  • Female subjects whose menstruation cycle coincides with the study periods.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00939367). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search